? Metabolomics Core Based on the success of the Cancer Metabolism Developing Shared Resource and growing scientific needs of ACC members, the ACC established the Metabolomics Core as a full-fledged Shared Resource, with an expanded array of services. Dr. Daniel Kelly, Ware Professor of Diabetes and Metabolic Diseases, has assumed leadership of this Shared Resource. Dr. Kelly is a well-recognized expert in mitochondrial metabolism and leader in the study of the metabolic origins of diseases in his over 25-year career. This new Shared Resource is staffed by Technical Director Dr. Christopher Petucci, along with a fully trained analytical chemist. Dr. Petucci has over 20 years of experience in mass spectrometry, including extensive expertise in measuring metabolites in cells, biological fluids, and tissues from animals and humans. The Metabolomics Core provides critically needed state-of-the-art targeted and untargeted metabolomics and lipidomics services to ACC researchers, which are extremely cost-effective compared to the out-sourcing used in the past. The Metabolomics Core: 1) provides well-validated, quantitative, targeted liquid chromatography-mass spectrometry (LC/MS) metabolomics of 127 metabolites from samples including cells, plasma, and tissues; 2) provides untargeted metabolomics and lipidomics platforms, for metabolite and lipid discovery; 3) performs LC/MS method development for custom metabolite assays tailored to individual needs; and 4) provides education and training in the use of the these technologies. The Metabolomics Core has four triple quadrupole mass spectrometers, two high resolution instruments (one for metabolomics and lipidomics, and one for protein quantification), Agilent 1290 Infinity HPLC and 6495B triple quadrupole mass spectrometers for targeted metabolomics and a Thermo Fisher Scientific UHPLC/Orbitrap ID-X mass spectrometer for untargeted metabolomics and lipidomics. ACC members accounted for 26 of 56 investigators (46%) using the Shared Resource during the most recent reporting period (07/01/18-06/30/19). As one example of high impact research dependent upon the Metabolomics Core Shared Resource, Dr. Carl June (Immunobiology) evaluated the attributes of CAR costimulatory domains and demonstrated that CAR-T cells with 4-1BB coreceptors increase respiratory capacity, fatty acid oxidation and mitochondrial biogenesis, in contrast to CAR-T cells with CD28 coreceptors which had metabolomics consistent with enhanced glycolysis in effector memory cells (Kawalekar et al., Immunity, 2016), which has already impacted clinical trial design. The Metabolomics Core is supported by the ACC in partnership with Penn's Cardiovascular Institute and the Institute for Diabetes, Obesity and Metabolism. The mission of the Metabolomics Core is to provide ACC members with a world-class platform providing new discoveries and insight into cellular metabolic mechanisms, which can be integrated with genetics, epigenetics, cell signaling, and other molecular bases of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016520-45
Application #
10088764
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-15
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Crisalli, Lisa M; Hinkle, Joanne T; Walling, Christopher C et al. (2018) Higher Donor Apheresis Blood Volumes Are Associated with Reduced Relapse Risk and Improved Survival in Reduced-Intensity Allogeneic Transplantations with Unrelated Donors. Biol Blood Marrow Transplant 24:1203-1208
Mazaleuskaya, Liudmila L; Salamatipour, Ashkan; Sarantopoulou, Dimitra et al. (2018) Analysis of HETEs in human whole blood by chiral UHPLC-ECAPCI/HRMS. J Lipid Res 59:564-575
Facompre, Nicole D; Harmeyer, Kayla M; Sahu, Varun et al. (2018) Targeting JARID1B's demethylase activity blocks a subset of its functions in oral cancer. Oncotarget 9:8985-8998
Rosenfeld, Aaron M; Meng, Wenzhao; Chen, Dora Y et al. (2018) Computational Evaluation of B-Cell Clone Sizes in Bulk Populations. Front Immunol 9:1472
Shroff, Rachna T; Hendifar, Andrew; McWilliams, Robert R et al. (2018) Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation. JCO Precis Oncol 2018:
Fraietta, Joseph A; Lacey, Simon F; Orlando, Elena J et al. (2018) Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med 24:563-571
Anton, Lauren; Sierra, Luz-Jeannette; DeVine, Ann et al. (2018) Common Cervicovaginal Microbial Supernatants Alter Cervical Epithelial Function: Mechanisms by Which Lactobacillus crispatus Contributes to Cervical Health. Front Microbiol 9:2181
Williams, Austin D; Reyes, Sylvia A; Arlow, Renee L et al. (2018) Is Age Trumping Genetic Profiling in Clinical Practice? Relationship of Chemotherapy Recommendation and Oncotype DX Recurrence Score in Patients Aged Ann Surg Oncol 25:2875-2883
Krump, Nathan A; Liu, Wei; You, Jianxin (2018) Mechanisms of persistence by small DNA tumor viruses. Curr Opin Virol 32:71-79
Bengsch, Bertram; Ohtani, Takuya; Khan, Omar et al. (2018) Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells. Immunity 48:1029-1045.e5

Showing the most recent 10 out of 1047 publications